Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What “updates” you talking about. The one from IC results. You mean the phase 2 that was to enroll 150 originally. The one that started enrolling in Oct 2012. Wow almost 6 years to enroll. Lightning speed. Hopefully we don’t have to wait the almost 6 years to recruit the first half of CLI. They need 123 for that. Going on the IC, they should get results for the first half in 2022. Amazing. Or are their trials enrolling quicker this time around. . Sheesh you would think they would mention that in the UPDATE if they were.
We got funds until mid 2019, no problem there. Even the Israeli grants have been shrinking the last 3 years. All the others involved in the trials via the grants, are the only ones with money remaining. But yet we’re going to get another set of grants for these trials. Ya right.
Deceased Deniros.
Here’s one of EichKing’s calls for you. Post dump of last year. There are others with uncanny accuracy. But like how the charts were clearly showing overbought right before dday, (you showed me a 2 year chart in a feeble attempt to back up that claim remember) they would have whispered that call to you like only a chart whisperer could.
Post 7782. Oct 31/17 Price $1.64
“EOY less than $1.40”
December 29/17. Price $1.38.
It IS just too easy!!!
Thanks for the reply. Agreed on all but one front. Would add a few things as well.
Not the best timing to try and get a partner on your terms with financing dwindling quickly. Potential partners are obviously not in any rush. No bidding wars here. They would have a pretty good idea of Pluristem’s situation. Some pretty smart people running these companies. We have wannabes. Going it alone has proved to be a big mistake so far. They have been holding out for years, and may just suck it up and take anything out of necessity. Gets worse and worse with each passing quarter. Hence Widestream
There’s a reason nobody looks for reimbursement from EAP. Want to keep actual manufacturing costs hidden. We had “sales” one quarter for $50 g’s with a cogs at $2’s. Hopefully our experienced management doesn’t get burned on that one. But desperate times call for desperate measures.
Really don’t have faith in our patents. Just search bioreactors, 3D bioreactors. They exist. One would think in direct violation of our patents. But who knows. Certainly don’t have the cash to test that.
And yes, I think that’s the only positive when it comes to Celularity.
You could add a few to the negative column. Experienced. Well connected. And the big one, they don’t have Zami his sidekick accountant steering the ship. Wonder if Kaki ever used the “solution in my pocket” walking in to a meeting with a potential partner. Wouldn’t surprise me in the least.
Scary competitor indeed.
Great job. Should have posted the link in the first place. Like I said, doesn’t matter. Didn’t find me telling people to sell?
So I’m curious to hear your take on their current financial situation.
Or any thoughts on Celularity’s upcoming readout on phase 2 Diabetic Foot Ulcer trial, where outcomes are the same as our CLI trial and then some.
Nobody dared to touch either of these two topics I brought forward. You up to the challenge?
Wasn’t so much about the stocks you chose. It’s the weird 4 month timeframe you chose. Funny the “peak” term wasn’t used originally to justify its use. Just seemed to match perfectly with the point you were trying to make. Any other normal timeframe would have shown quite a different story with ATHX and BCLI. Doesn’t matter to me what Auto bought or sold.
Here’s pluristems numbers.
5 day... $1.18 to $1.12(right now for all of them)
1 month $1.32 to $1.12
6 month $1.24 to $1.12
YTD $1.44 to $1.12
1 year $1.97 to $1.12
5 year $3.29 to $1.12
Pretty ugly unless you customize timeframes. Both BCLI and ATHX have multiple upside swings in these commonly used timeframes.
Really? You’re going to take numbers off the site that was shown to have fictitious numbers too? Maybe all the tute buys over our history may add up to the total they said. They just forget to decrease it by the number of sells. Would most likely be back to the 4–5% most people accept.
Not saying Ark does or doesn’t have what you stated. Would like to see it from a different source that all. One that hasn’t been proven to have fake numbers on it. Not that I care, as it is irrelevant. Just making a point.
And while you’re at it, why don’t you find me one single post of mine where I told someone to sell their shares. My posts to Hopepotentialster don’t count. That was there for a different reason to make my point.
Well said Jack. A few have been saying this for a long time now. And although I poke fun at things and posters that get under my skin with fictitious claims, there’s nothing funny about losing money, which pretty much everyone here, has, by admission or not. These twins truly are nothing but a couple of clowns. No disrespect for clowns intended.
Distorted? I have been using by exact quotes from you and kindly giving the post number for all to see for themselves. Classes? No thanks. I don’t “invest” on hopes and potential. I did before as I believed what this management was saying for many years. Luckily I walked away unscathed, only because I averaged down when we were trading under a buck, and I sold all my shares for very small gain. So small I would call all the years I had money in their shares, dead money.
My in depth research into upper management and board showing zero biotech experience and little experience period, an absolute necessity in this complex field, helped change my mind. . The promotion of the accountant to co-ceo. The purge of talent we brought over from Elbit Vision Systems we got. Textile industry to biotech...great call. Zami, if he was such a great visionary, would have hired experienced professionals from the industry to all the top positions. Not get the head of Human Resources from Elbit as well.
I will admit, it was my first venture into this space. I bought the saving of the young girl on her deathbed “miracle”. And this space was in its infancy. I just happened to pick a dud.
But I have and will continue to gamble on hopes and potential via cheap, leveraged options. So far I can’t even pull a pair of 2’s. But I will continue until something miraculous occurs like a buyout or a major stockpiling agreement is attained, or the lights go out for good. At 52 week lows in the year of the shareholder, sadly the latter inches closer each quarter.
$1.07 and you’re stil LOLing. Not sure what price it will take to make it stop. “Tobias” “Scientists” “No Bad News” “TOBIAS” “SCIENTISTS” “NO BAD NEWS”. ALL IS WELL!!!
If we break through a buck, they’ll make the call for the rarely used rating, “screaming buy.” I guess that’s why they’re the “pros”. Everyone should start listening to them. Maybe in another 5 years they will be correct. I must have missed the downside risk section in these professional reports. At least they would have gotten them correct.
I don’t selectively pick out your posts. I pick out each and every one where you made a call based on your TA. I guess that is selective, but you know where I’m coming from. And each and every one of them was wrong. I even told you I’d give you a win if we make it to the $1 to $1.10 like you called. Even though you repeatedly called for a quick drop once $1.20 was broken.
Now you somewhere made a call of a bounce off $1.10??? You didn’t sorry. If someone called me out on a claim I made, I would go find it myself to prove them wrong. But you ask that if others. You and I both know it doesn’t exist, at least not on this board, and that’s the only reason you ask me to. Give me an impossible task as if I don’t produce it, it must be true. It isn’t sadly.
Here is your actually there in post 16649 on Oct 10th.
“Technical Breakdown has occurred. More pain ahead with the 1st stop between
$1.00 and $1.10.
Breaking $1.00 then a projection toward $.75 is quite possible”
First stop was almost 2 weeks between $1.10 and $1.20.
Yes after we broke through $1.20 and hovered just below, the call changed to must break through $1.20 or lower prices will come. Wow, what a call. All while we’ve been drifting lower for over a month now. Wow what a call change.
I think I’ll go out on a limb here with my call. If we break $1.10, we may head down to $1 to $1.05, possibly even break $1. Especially if no news comes out. If we hold and maybe get some news, could go back up to the high teens, and will have to punch through $1.20 to continue higher. We will see which direction gives me a win. Only way I lose, is with sideways action.
Yes even me using the wrong term, you understood what I meant. It is basic investing no matter how you look at it. No deep TA necessary.
I’m sorry you don’t find my factual post on their financials not USEFUL. Yes you used caps. Funding a tiny company in this expensive company is irrelevant. Showing with their current burn rate, they won’t last a year without raising more funds. Or invoking their emergency cost cutting plan they have in place, if they can’t increase their funds. Me thinks that post is getting buried again.
Probably not important though. And no correlation to our declining price. Uh oh, don’t look now, we broke $1.10. You got your first win. Hooray!!! Too bad it’s not so great for your “investement”. Should have practiced what you preach.
Not what I was insinuating at all. Showed that Menora Mivtachim sold all their shares. Holes everywhere on that page. I’ll stick with approximately 4-5% tutes at most. You could be right on insiders at 11%. Free share lottery for employees already passed. At this rate, they should be allocating 40 million shares for employees. 30 of it, to entice the twins services. Otherwise it would be back to Elbit Vision Systems for the both of them.
If you look at what they said, top 10 tutes hold just under 40%. Add up the top 10 and they hold approximately 18 million shares. Far cry from 40%. Unfortunately even the big sites post misinformation. Would have been good though.
Like always, care to provide a post where you made this “call”. Resistance of $1.20 must hold...or a quick drop to the $1 to $1.10 range is what I remember.
Every week or two, it changes. Everyone knows there are resistance levels on both the upside and the downside. Like if we break below $1.10, the next would be a buck. Or on the upside, we break $1.20, next would be $1.30, holding $1.20 on the downside. It’s not rocket science. No need for deep chart analysis. It’s basic investing. Basic!!!
At least if you had sold upon breaking your call of “must hold” $1.20, I’d at least give you props for having convictions for your strong belief in what you preach. Right or wrong. Unfortunately YOU don’t even believe what you’re saying on this board.
Hey Voova,
I would like nothing more than for that link to be correct. I highly doubt it is. I will provide 2 different links that show Menora Mivtachim sold their entire 1 million shares. And these are from their latest quarterly 13f report in August.
https://stockzoa.com/fund/menora-mivtachim-holdings-ltd/
https://fintel.io/so/us/psti
You asked for it. You got it!!!
Mistake 1?
Where did I dismiss the value of professional researchers as a whole? I have dismissed the value of researchers as it applies to Pluristem, and have provided reasons for their lofty “evaluations”. To hopefully get commissions if they’re chosen to do their raises. I truly am sorry you don’t understand conflict of interest and the implications they bring. See also, mistake 5 below.
Mistake 2?
I do dismiss the value of ta on a stock like this. You believe and what has it done for you? Haven’t made a correct call yet. And even when the charts say it’s going to move lower by about 20% plus according to your “analysis”, you don’t even take your own advice. So what’s the point.
Mistake 3?
I haven’t dismissed them thank you. I have criticized them on the agonizingly slow advancement of them. Or the wasted money changing direction, 2 year delay building out manufacturing. Others have caught up. 15 plus years of this and basically just starting phase 3 trials in 2 indications. One with Celularity right on their heels now, and one with no competition because nobody wants it.
It’s a “strategic collaboration” with thermo. Not a partnership, at least for now. Zamis bragged about in house manufacturing since day one that will suit their needs. Now they need to partner for it? We will see soon enough if Thermo throws them a bone for their 3D technology. All it is imo, is a way for them to try and get some much needed cash. They were actually the pioneers at one point. Did nothing with it except let others catch up.
Lonza, Sartorius, Thermo and others saw the opportunity and ran with it. I just hope Thermo finds a use for it.
They’ve been promising partners for years. Then changed it to they’ll only partner after phase 2’ are complete. Now we live in limbo. I could go on and on if you want.
Mistake 4 and 5? Lumped together.
H.C Wainwright Sept 14, 2015 Target $4
https://www.smarteranalyst.com/analyst-insights/analyst-opinion/h-c-wainwright-reiterates-buy-on-pluristem-therapeutics-inc-following-fy4q15-financial-results/
H.C. Wainwright July 19, 2016. Target $3.50
https://www.smarteranalyst.com/analyst-insights/h-c-wainwright-analyst-assumes-pluristem-therapeutics-psti-affirms-buy/
FBR July 11,2016 Target $3
https://www.smarteranalyst.com/analyst-insights/fbr-capital-analyst-bullish-pluristem-therapeutics-inc-ptsi-following-pipeline-study-plans/
Need I go on? I have more if you like. What’s the point. Never right. Waste of time. Year after year of pretty much the same target price. How long are they expecting people to wait, a decade? Usually a 52 week target. Jokes.
Now for the whopper you said. Downside risk. Find me one analyst report stating downside risk. That one takes the cake. Never once has any downside risk been put into any of these reports.
I’ve pointed out your mistakes. Sorry I have yet to find one without.
How long term we talking since 5 years is too short. LMBO
Nothing illegal about it, so why would the sec step in.
Unfortunately they might not be around for the years you are willing to wait. Didn’t you read my post in their finances. Did you prove that one wrong? . LMBO
I’m not the one who made the mistake right. I clearly pointed out YOUR mistake, that you finally admitted after a dozen or so failed attempts to validate.
An analysts rating is absolutely useless when there are CLEAR conflicts of interest. Kind of like a financial advisor trying to steer you into a mutual fund that pays him the most commissions. Or reading a report from someone who was paid by the company to write a report on.
And don’t you find it weird that not a single one of these “analysts” has made a correct call on the direction of the stock. Getting closer to being down 50% for the year? They are the “pros” right. You could almost call all the beliebers here analysts.
Please find one single analyst in the past 5 years of this stock that has made a correct call on the upside. There HAS not been a single one. So keep that as your valuable tool to help you “invest”. Along with charts, you are exactly where you should be. DOWN on your “investment”.
Yes it is a waste of time. I’m not the one making false claims over and over again. Did you correct Hopester?Only Tobias quotes about Pluristem wanted. Analyst opinions good. Tobias good. No bad news good. Scientists good. Facts bad.
“Tobias” “Scientists” “No bad news” “Tobias” “Scientists” “No bad news”
Pretty much summed up the quality work from one poster that wants some serious discussions, but yet avoid them at all costs.
I’m sorry you think correcting FALSE claims is knit picking. I don’t. The days still early so this topic could be revisited again unfortunately.
And I take it you didn’t read the link I provided about analyst’s conflicts of interest. Since 2 out of the 3 BUY’s you found have been involved with Pluristem, it’s quite relevant. And the third is most likely courting Pluristem for their next round.
And no I didn’t miss your point. In fact I gave you info on why your point really has no merit. A point of mine that was obviously missed. There’s a whole other world out there besides charts. I’ll cut and paste for you to save time. Your welcome.
“Potential Conflicts of Interest
Many analysts work in a world with built-in conflicts of interest and competing pressures. On the one hand, sell-side firms want their individual investor clients to be successful over time because satisfied long-term investors are a key to a firm's long-term reputation and success. A well-respected investment research team is an important service to customers.
At the same time, however, several factors can create pressure on an analyst's independence and objectivity. The existence of these factors does not necessarily mean that the research analyst is biased. But investors should take them into account before making an investment decision. Some of these factors include:
• Investment Banking Relationships—When companies issue new securities, they hire investment bankers for advice on structuring the deal and for help with the actual offering. Underwriting a company's securities offerings and providing other investment banking services can bring in more money for firms than revenues from brokerage operations or research reports.
Here's what an investment banking relationship may mean:
•
1 The analyst's firm may be underwriting the offering—If so, the firm has a substantial interest—both financial and with respect to its reputation—in assuring that the offering is successful. Analysts are often an integral part of the investment banking team for initial public offerings—assisting with "due diligence" research into the company, participating in investor road shows, and helping to shape the deal. Upbeat research reports and positive recommendations published after the offering is completed may "support" new stock issued by a firm's investment banking clients.
2
3 Client companies prefer favorable research reports—Unfavorable analyst reports may hurt the firm's efforts to nurture a lucrative, long-term investment banking relationship. An unfavorable report might alienate the firm's client or a potential client and could cause a company to look elsewhere for future investment banking services.
4
5 Positive reports attract new clients—Firms must compete with one another for investment banking business. Favorable analyst coverage of a company may induce that company to hire the firm to underwrite a securities offering. A company might be unlikely to hire an underwriter to sell its stock if the firm's analyst has a negative view of the stock.
6
• Brokerage Commissions—Brokerage firms usually don't charge for their research reports. But a positive-sounding analyst report can help firms make money indirectly by generating more purchases and sales of covered securities—which, in turn, result in additional brokerage commissions.
•
• Analyst Compensation—Brokerage firms' compensation arrangements can put pressure on analysts to issue positive research reports and recommendations. For example, some firms link compensation and bonuses—directly or indirectly—to the number of investment banking deals the analyst lands or to the profitability of the firm's investment banking division.
•
• Ownership Interests in the Company—An analyst, other employees, and the firm itself may own significant positions in the companies an analyst covers. Analysts may also participate in employee stock-purchase pools that invest in companies they cover. And in a growing trend called "venture investing," an analyst's firm or colleagues may acquire a stake in a start-up by obtaining discounted, pre-IPO shares. These practices allow an analyst, the firm he or she works for, or both to profit, directly or indirectly, from owning securities in companies the analyst covers.”
Funny if you look at the pie chart, it has a shade of blue there. If you go to the “buy” colour, it’s an exact match. They even put a 3 beside the buy to help people out. Not strong buy but buy, yet again. Glad they name the “analysts” too. Another reputable source. Great find!!! Keep up the great work!!! It’s current!!! It’s current!!! All is well!!! ALL IS WELL!!!
Wow you remind me of the knight in the Holy Grail. Going to wear boots today. Don’t want my ankles to be bitten.
Hey Jack. Still “happy” with Pluristem too?
Post 7610 Oct 26, 2017. 1 day before dday.
“My prediction for end of year is $4.32. Why? I have some faith that we will hear some pretty good news, but not the great white whale news. That will likely come in 2018 imo. That number is unfortunately what I bought SOME shares at back in 2012, after rising up from my original purchase price of $1.15... thought it was all uphill from there lol. Oh what we learn. Have since averaged share cost to $1.70 and have about 3x my shares owned leveraged between December and March options. Stoked for both! “
Now let me guess. You sold your options that day or the next. Being so stoked and all. And calling for $4.32 by end of year. You even said the raise was pretty good right after.
Sure you could have sold them for around $.30 or $.40 right around then. After the dump, not so much. Dropped right back down, and stayed there until they became worthless. Did they expire worthless on you too? And you actually got some way back then for $4.32. Wow what a steal. You dove right in on that pump huh. OUCH!!! And you’ve averaged down all the way to $1.70. How many shares you have to buy to accomplish that.
And what about the actual shares at an average cost of $1.70. Still have them or did you bail on them the next day too. I bet you did...NOT. On both counts. Your moves are right there for everyone to see. Wouldn’t throw stones calling others bad investors. There’s more posts of yours out there, showing your investing prowess. Let me know and I’ll gladly refresh your memory.
Wow, truly one of a kind. Hopefully the white flag will come out finally after this post. I will tell you again. Not sure which part is confusing you. The Nasdaq link you show is wrong. Incorrect. A lie. Says right there info provided by Zacks. You can search yourself for other sites to find the truth, which is what I’ve been telling you over and over again to no avail. Get back to us when you find the “strong buy”.
I will provide you a link to the Nasdaq site you can’t seem to get over that shows what really happened. Look down to the “News for PSTI” section. Fourth one down. From Sept 28, 2018. One, two, three, then four. If it helps, think of your chart showing down 4 pennies.
“H.C. Wainwright Sticks to Its Buy Rating for Pluristem (PSTI)”
https://www.nasdaq.com/symbol/psti/stock-report
And here’s where that link will take you, showing the whole thing.
https://www.smarteranalyst.com/brief/h-c-wainwright-sticks-to-its-buy-rating-for-pluristem-psti/
Now for FBR from July 31, 2018
“B.Riley/FBR initiates coverage on Pluristem Therapeutics (NASDAQ: PSTI) with a Buy rating and a price target of $4.50.Analyst George Zavoico ...”
https://www.streetinsider.com/dr/news.php?id=14450100
And to corroborate.
https://thefly.com/landingPageNews.php?id=2767149&headline=PSTI-Pluristem-initiated-with-a-Buy-at-B-Riley-FBR
Could very well be right. One thing though. Raises and dilutions are the only areas of expertise our board members have. Yes with startups, but we hung on to them all this time for this reason alone. Gave most of them 500K+ shares for that. It was built around it from day one.
No strong buy anywhere sorry. I gave you actual proof of the actual ratings. I posted a link to Maxim’s site where YOU told me to go. It’s not there. Fictional strong buy. Maybe that’s why Saud came out and said he’s never seen one before. Because he hadn’t and still hasn’t. All buys. All of them. Still irrelevant as conflicts are all over these pretend ratings. Absolute joke. May have found something more of a joke than the sharts. But you believe the Nasdaq site. It did you well with the insider buys joke. It’s no wonder you post in CAPS when you’re PROVEN wrong. One step away from the I’m rubber you’re glue...
I’ll even give you a link to some much needed reading. All about conflicts of interest with regards to analyst ratings. From the sec.gov website. Now that’s a pretty reliable site for their info. Zacks is not, but you don’t want to believe that now do you. It’s from 2010, but don’t worry. It’s still relevant.
https://www.sec.gov/tm/reportspubs/investor-publications/investorpubsanalystshtm.html
This is the one company that could leap frog right over us in a heartbeat. Their diabetic foot trial has most if not all outcome measures we do, and are expecting phase 2 results in November. Then who knows what the FDA could grant them. It is, a serious disease after all, that meets an unmet need.
Would sure make the two year delay by Zami to build out manufacturing, a momentous gaff on his part. Time will tell.
https://clinicaltrials.gov/ct2/show/NCT02264288?term=Celularity&rank=5
Ain’t that the truth. Wonder what price the “players” will get the price up to first, in order to get the next dilution done. Maybe $1.40 to $1.50 so they can take us right back where we are now, after the steep discount of course.
Must have missed your link. My bad. Copy and paste the link next time and you’ll be golden.
So I did what you asked. Not entirely sure I see what you’re talking about, since their rating remains at buy. Or are you still talking about the Nasdaq site’s fictitious strong buy rating. Or did they just downgrade in the last couple hours. I’ll even be kind enough to provide you the link. Please advise where I went wrong.
http://www.maximgrp.com/wp-content/uploads/2018/10/Research-Universe-10.19.2018.pdf
But keep missing the main point of my argument. Argue that. Search that instead of looking for a “strong buy” recommendation.
Unlike you, I don’t make any sort of recommendations for what someone should do when it comes to Pluristem. Feel free to go back and check.
I don’t brag of 25K purchases, or tell people if the stock hits a certain price, it would be a good time to buy. Or sell. You seemed to have made that call to sell just recently, yet didn’t yourself.
I don’t try to pretend I’m an analyst and have said that many times before. I just don’t care for others that come on here boasting of their big buys that are well under water now, yet have absolute zero concern about anything. Not one single concern that has ever been posted.
I have provided many posts on the bio’s of our management team, pointed out their many blunders, missed milestones, and thoughts on their financial situation. Which, imo, will not take them to the first quarter of 2020 like they said, without a cash infusion from a partner, a stockpiling contract, dilution via a raise, or dilution via an ATM. Or the dreaded cash saving contingency plan that rears it’s ugly head again in their quarterly reports.
They’ve been touting partnerships for many years little success. Yes the US government is paying for the costs of their trials, but it’s a far cry from the $50 mil to $200+ mil others have gotten perform their trials. And they’ve been touting a stockpiling contract since what, the beginning of 2017. Only thing they’ve been good at is dilution any way they can. But they’ve used that too many times now with broken promises abound. Each time it gets worse and worse, and dread the terms of/when the next one comes.
I’ve told you my position before yet you want it again. I buy options as far out as I can for as cheap as I can. The leverage keeps the cost down. If they manage to pull something off, it will pay big. If they don’t like they have so far, my options become worthless quarter after quarter. I wouldn’t waste my money if I thought there was zero hope. It’s a long shot at best. Hence why I say I like to gamble. That is what this stock is, not an “investment”
Now a question for you. When you first came to this board you were critical of management and said the market was too. Now you call them “good”. What changed your mind since March of this year.
I don’t know why you keep coming back for more, but here goes. You continue to use strong buy in your post. You did put a buy/strong buy this time, but wouldn’t that imply strong buy is still there. Maybe Zzatt can assist on what that infers. Funny the two companies listed from the link YOU provided, have buys. See prior post for facts. So did you find some strong buy recommendations? Or were you wanting me to find the missing 3rd analyst’s strong buy call for you. I asked you to show me the strong buy call, but you didn’t come through.
Now you want to bring up Maxim. Another company that has been involved in Pluristem’s raises. I could be wrong, but I remember them having an $8 price target in 2012. You know, the time the first pump happened where Zami managed to sell a bunch of shares right at the absolute peak of $5 in 2012. The one where the “saved” girl died, without Pluristem “knowing”. They do have lawyers on their board to make sure they don’t fly too high to get burned. But go to the sec.gov site to research instead of Nasdaq. Their information comes from Zacks.
I’m sorry you can’t see any conflicts of interests in these “analysts” recommendations. Or why their “recommendations” could be jaded to suit their needs. Two of the three you mentioned now, I have shown their relationship to Pluristem. Well one, but just do a search for Maxim and Pluristem and I’m sure you’ll find it all by yourself. If you find the missing 3rd one, I’ll find that one too. They wouldn’t want to try and entice Pluristem to use their services and get big commissions, with no “recommendation” or a hold or sell on it, would they? Heck even for their clients that may have taken part in the raises. How would that look if they changed the rating to sell.
So you want to base your decisions on these recommendations, feel free. Back the truck up once the charts tell you. I’ll answer your other question in another post. I’m not known for keeping posts short, but I’ll do my best.
What was so unintelligible in that post? All the big numbers?
But but but, they said on their presentation they have $28 mil in funding. No intentional mislead there huh.
Don’t give them any ideas. Could very well be the next indication they chase. Or at least go for orphan drug status so they can shelve that too. Only after forming a steering committee though.
1. I use that term as they’re as valuable as one on a stock like this.
2. Yes one just reaffirmed. HC Wainwright. I guess you didn’t see where I was going with that one. Maybe this will help.
“HAIFA, Israel, Jan. 25, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI) announced today that H.C. Wainwright & Co., LLC, the sole book-running manager of its previously announced bought offering of 12,244,898 shares of common stock and warrants to purchase up to 7,346,939 shares of its common stock, has exercised in full its over-allotment option“
It’s pretty amazing that an underwriter would reaffirm it’s buy rating. Not strong buy, but buy. I’ll even show you.
“Pluristem Therapeutics (NASDAQ:PSTI)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Friday, September 28th“
Either way, no conflict there eh. Like I said, writing on the wall as to what’s on the horizon.
3. Yes many have had buy ratings the entire way. So pretty much just a token rating. Many have come from companies with direct relationships to Pluristem. Again, see point number 2.
4. Just trying to steer people away from checking 1 site and making claims of insider buys. Pretty big difference between 910,000 at market buys or 910.000 gifted shares. Even the “strong buy” claim with the link provided was false. Here’s the second company your research shows as a “strong buy” from July 31st of this year. But please inform us of when the upgrade to strong buy happened. And who’s the mysterious 3rd “analyst” they show? Quality site for some fantastic DD.
B.Riley/FBR initiates coverage on Pluristem Therapeutics (NASDAQ: PSTI) with a Buy rating and a price target of $4.50.Analyst George Zavoico ...
Kind of makes you wonder if FBR will be involved in their next raise. And you’re welcome by the way. For correcting some errors in your all caps post. No need to be angry. You’re pretty new here and don’t know the game yet.
HC Wainwright was the underwriter for the first dilution early last year. Wonder why they would give such a glowing recommendation. Hard to peddle a raise with a proper evaluation. It’s pretty telling as well as to what is imminent. What kind of price discount they will give is the big question. But keep trying.
“Analysts” covering Pluristem have been saying that since day 1. At least a $3 target. Should go back and check it out. Back the truck up with those 2 whopping recommendations. Or see if they were affiliated in any of Pluristem’s dilution events. And you should continue to use Nasdaq site for your DD. It did you well when you saw they had a fictitious 910,000 insider buys. Almost as valuable as a shart. But at least it shows why you stick with sharts.
Look at the financials part 2.
So here we are, most likely sitting around $20 million left (Depending on ATM usage). A company that refuses to give any guidance, explanations, ridiculous updates that are truly laughable. Our stock narrowing in on their 52 week low.
Now I made a mistake on my last post. Feel free to quote that and poke fun. The effort is quite humorous. Just like missing periods I stated total grants of $11.6 mil, but it was actually $12 mil in total. So they have $2.1 million in grant money left as of June 30/18.
On Kaki’s turn for the big “update”, he states they used $5.8 mil in cash last quarter. During this same quarter, they realized $1.5 million in grants to offset R&D expense. I showed previously (to those who “read”) that the grant money is, or just about gone. Assuming of course, that they’ve used it in the last 4 months since fiscal year end.
Now take away the grants and imagine a $7.3 million quarterly burn rate with $20 mil in cash. Do we really have enough to take us to the first quarter of 2020 like they stated? A little more concerning don’t you think.
The ATM boosted cash by $2.6 million last quarter. But how long can this continue, especially with a declining share price like we have. Like I said, quite the predicament our great, experienced leaders face.
But yes, Zami deserved that year end raise. Poor guy had t got one since 2011. Only several million free shares. Boohoo. But don’t forget, they got the cost cutting contingency plan in place, just in case. Would love to see if involves either of the twins taking a pay cut. Extremely unlikely.
But no analyst or pretty much anyone could see this. Those analysts that work for tutes and such, are probably just chartists. But yes we have the scientists on our side. No analyst covering the biotech sector, could ever have a deep knowledge and serious schooling with degrees related to the biotech sector. Pretty much zero difference covering banks or covering biotechs. They just wing it with trial results, and it probably just flies over their heads. As long as the p values less than .05, they’re good. They probably scour the boards looking for the great scientific knowledge we have on this board. Go Tobias!!!
You want to understand why our price is sitting near our 52 week low, I think I’ve pegged it. That and the fact that nobody in this industry believes anything our management says.
Would love to hear someone try to counter this. I’m surely not holding my breath. Everyone just go to their happy place and it will all work out. Next news release you can yell at me to eat my words again, while we end the day lower.
Anxiously await the next quarterly coming in a few weeks. Will be telling with regards to their financial situation.
I think we are going to see in the next 2 quarters the fate of the company. Personally I think wothout a stockpiling deal or a partnership with substantial upfront cash, we are toast. We truly need cash soon and a dilution either by a raise or uptick in ATM, will take us to 10 year lows and beyond.
We could go down to $.70 and they would still be touting Tobias and the twins. “I’m not worried”. All is well. All is well!!! The way they stick up for the goon squad really makes you wonder.
Not a care in the world about lack of transparency. No concern as to why they don’t release updates on enrolments. No quarterly conference calls. Just took a quick look at Cytori and they do cc’s. Update numbers too. Brainstorm does too. Athersys too. Just mention these as they have been mentioned as well. But Zzatt likes to chalk it up to being the norm in biotech. I’m sure it is the norm... for crappy companies. Would love to see him give examples of other biotech’s that don’t as well. All under a buck most likely. But all I checked so far do cc’s.
Just like their claims of comparative executive compensation for similar stage biotech’s. Yet when asked to give examples, crickets. Have never seen any similar size biotech company give away that absurd amount of free shares, not to one, but 2 clowns sitting on top.
And they’ve been in for a year and a half, down on their gamble, and yet don’t understand the concept of DEAD MONEY. Especially for someone who reads a thesaurus for fun. Or polices the board for missing periods. Now they pretend not to read to avoid getting schooled. They still get schooled. They just don’t “see it”. Too funny.
Go Zami !...!_ _!...!
What a year end update. Blew my socks off. This management DOES know what they’re doing. We don’t care about updates on trial enrolment. We want to hear about grants that you’ve almost used your entire direct portion on. They got results from an IC trial? Where was I. Did I miss the big price gain? Rehashing news of the year IS pretty transparent. What was I thinking. I think the second time I hear it makes it sound better. BELIEBERS lapped it up. We love you Zami!!!!! !...! !...! Rock on Zami!!!
HAIFA, Israel, September 27, 2018 - Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today reported financial results for its fourth quarter and fiscal year ended June 30, 2018 and provided a corporate update.
“The indications we are pursuing for our novel cell therapy products, PLX-PAD and PLX-R18, target underserved medical conditions for which there are no viable treatment options today,” stated Yaky Yanay, Co-Chief Executive Officer and President of Pluristem. “With our two ongoing pivotal Phase III trials for PLX-PAD in critical limb ischemia (CLI) and muscle recovery following hip fracture surgery, both collectively supported by over $16 million in non-dilutive grants, we are progressing toward our goal of offering patients a new, innovative, regenerative medicine option that can improve mobility, shorten hospitalization time and ultimately save lives.”
Mr. Yanay continued, “During the fiscal fourth quarter, we achieved a number of significant milestones across both of our development programs. In PLX-PAD, we reported positive data from our Phase II clinical study for the treatment of Intermittent Claudication (IC), an earlier stage of PAD. In PLX-R18, we entered into an additional collaboration agreement with the U.S. Department of Defense to study PLX-R18 for the treatment of long term lung injury following exposure to mustard gas. We also reported positive data from our ongoing collaboration with Fukushima Medical University evaluating PLX-R18 as a treatment for radiation damage to the gastrointestinal (GI) tract and bone marrow. Finally, we announced a strategic collaboration agreement with Thermo Fisher Scientific to advance fundamental knowledge of cell therapy industrialization and to improve quality control of the end-to-end supply chain.”
“September is Peripheral Artery Disease (PAD) awareness month. Pluristem is committed to developing a viable medical solution for this troubling condition and we are proud to be on the cutting edge of regenerative medicine through which we aim to give hope to millions of PAD patients around the world,” Mr. Yanay concluded.
Financial Update:
As of June 30, 2018, Pluristem had $30.6 million in cash and cash equivalents, bank deposits and restricted deposits. The Company’s net cash used for operating activities during the fourth quarter was $5.8 million.
You should just put me on ignore then. Save the 15 seconds or so for more quality time with Tobias. Shwiiinnnngggg!!! Great “Happy” place.